Retirement Systems of Alabama Boosts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Retirement Systems of Alabama boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 998,307 shares of the biopharmaceutical company’s stock after acquiring an additional 236,453 shares during the quarter. Retirement Systems of Alabama’s holdings in Gilead Sciences were worth $92,214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. nVerses Capital LLC purchased a new position in Gilead Sciences during the third quarter valued at $25,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the fourth quarter valued at $29,000. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. Finally, Crews Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter valued at about $31,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock worth $53,611,715 in the last ninety days. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Down 0.4 %

NASDAQ GILD opened at $97.99 on Wednesday. The firm has a market capitalization of $122.12 billion, a PE ratio of 1,088.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The company has a 50-day simple moving average of $92.58 and a 200-day simple moving average of $86.14. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $99.45. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the firm earned $2.29 EPS. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

GILD has been the topic of several research reports. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Truist Financial boosted their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Sanford C. Bernstein started coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. Finally, Barclays upped their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.